Patents by Inventor Hans-Juergen Krause

Hans-Juergen Krause has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PROTEIN FORMULATIONS AND METHODS OF MAKING SAME
    Publication number: 20230007847
    Abstract: The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.
    Type: Application
    Filed: January 25, 2022
    Publication date: January 12, 2023
    Inventors: Wolfgang Fraunhofer, Annika Bartl, Hans-Juergen Krause, Markus Tschoepe, Katharina Kaleta
  • FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS
    Publication number: 20220241415
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Application
    Filed: September 10, 2021
    Publication date: August 4, 2022
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Protein formulations and methods of making same
    Patent number: 11191834
    Abstract: The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.
    Type: Grant
    Filed: December 29, 2020
    Date of Patent: December 7, 2021
    Assignee: AbbVie Biotechnology Ltd
    Inventors: Wolfgang Fraunhofer, Annika Bartl, Hans-Juergen Krause, Markus Tschoepe, Katharina Kaleta
  • Protein formulations and methods of making same
    Patent number: 11167030
    Abstract: The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductivity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.
    Type: Grant
    Filed: December 29, 2020
    Date of Patent: November 9, 2021
    Assignee: AbbVie Biotechnology Ltd
    Inventors: Wolfgang Fraunhofer, Annika Bartl, Hans-Juergen Krause, Markus Tschoepe, Katharina Kaleta
  • PROTEIN FORMULATIONS AND METHODS OF MAKING SAME
    Publication number: 20210121567
    Abstract: The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductivity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.
    Type: Application
    Filed: December 29, 2020
    Publication date: April 29, 2021
    Inventors: Wolfgang Fraunhofer, Annika Bartl, Hans-Juergen Krause, Markus Tschoepe, Katharina Kaleta
  • PROTEIN FORMULATIONS AND METHODS OF MAKING SAME
    Publication number: 20210113695
    Abstract: The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.
    Type: Application
    Filed: December 29, 2020
    Publication date: April 22, 2021
    Inventors: Wolfgang Fraunhofer, Annika Bartl, Hans-Juergen Krause, Markus Tschoepe, Katharina Kaleta
  • FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS
    Publication number: 20210113694
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Application
    Filed: December 18, 2020
    Publication date: April 22, 2021
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • PROTEIN FORMULATIONS AND METHODS OF MAKING SAME
    Publication number: 20190358322
    Abstract: The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.
    Type: Application
    Filed: December 20, 2018
    Publication date: November 28, 2019
    Inventors: Wolfgang Fraunhofer, Annika Bartl, Hans-Juergen Krause, Markus Tschoepe, Katharina Kaleta
  • FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS
    Publication number: 20190054171
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Application
    Filed: March 12, 2018
    Publication date: February 21, 2019
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS
    Publication number: 20180339046
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Application
    Filed: August 7, 2018
    Publication date: November 29, 2018
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Formulation of human antibodies for treating TNF-alpha associated disorders
    Patent number: 9950066
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Grant
    Filed: April 11, 2016
    Date of Patent: April 24, 2018
    Assignee: AbbVie Biotechnology Ltd
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Formulation of human antibodies for treating TNF-alpha associated disorders
    Patent number: 9750808
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: September 5, 2017
    Assignee: ABBVIE BIOTECHNOLOGY LTD.
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Formulation of human antibodies for treating TNF-alpha associated disorders
    Patent number: 9738714
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: August 22, 2017
    Assignee: ABBVIE BIOTECHNOLOGY LTD
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Formulation of human antibodies for treating TNF-alpha associated disorders
    Patent number: 9732152
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: August 15, 2017
    Assignee: ABBVIE BIOTECHNOLOGY LTD
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS
    Publication number: 20170158759
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Application
    Filed: January 27, 2017
    Publication date: June 8, 2017
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS
    Publication number: 20170151329
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Application
    Filed: January 27, 2017
    Publication date: June 1, 2017
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • PROTEIN FORMULATIONS AND METHODS OF MAKING SAME
    Publication number: 20170143828
    Abstract: The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductivity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.
    Type: Application
    Filed: February 2, 2017
    Publication date: May 25, 2017
    Inventors: Wolfgang Fraunhofer, Annika Bartl, Hans-Juergen Krause, Markus Tschoepe, Katharina Kaleta
  • FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS
    Publication number: 20170145087
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Application
    Filed: January 27, 2017
    Publication date: May 25, 2017
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Powdered protein compositions and methods of making same
    Patent number: 9610301
    Abstract: A method for preparing a protein or peptide powder is provided that includes spray drying a solution including more than, e.g., about 50 mg/mL of a protein or peptide (e.g., an antibody or antigen binding portion thereof), and at least one excipient. Also provided are stable powdered compositions including a protein and an excipient having less than, e.g., about 6% residual moisture.
    Type: Grant
    Filed: January 15, 2009
    Date of Patent: April 4, 2017
    Assignee: ABBVIE DEUTSCHLAND GMBH & CO KG
    Inventors: Peter K. Lassner, Michael Adler, Geoffrey Lee, Hans-Juergen Krause, Michael Siedler
  • FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS
    Publication number: 20170056498
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Application
    Filed: April 11, 2016
    Publication date: March 2, 2017
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes